AMSBIO (Abingdon, UK) and Sanguine Biosciences (CA, USA) have recently announced their agreement to distribute and support products and services throughout Europe.
For use in biomarker research, Sanguine collects and de-identifies biospecimen and other data, such as medical history, from patients with severe and chronic disease. Although this process is normally carried out in hospitals by medical staff, Sanguine provides a service that connects directly with patients and is capable of follow-up. According to Phillip Pridham-Field, Market Manager, Biorepository Services at AMSBIO, “Sanguine’s approach to biospecimen collection and their high patient retention allows researchers to collect the data they need with better turnaround time and with the potential for longitudinal studies”. He continued, “We believe their extensive biospecimen library will be an excellent addition to our current product offerings for researchers in life sciences.”
Sanguine is capable of collecting samples in patients’ own homes in major US cities. Patients are then able to track the use of their specimen data online. According to Brian Newman, Chief Executive Officer and Founder of Sanguine, “There is no denying that personalized medicine has become a significant area of interest for drug discovery, but there exists a gap between researchers who require biospecimen respective medical data, and patients who want to be a part of research efforts. We have engaged hundreds of patient subjects, and built a library of specimen and data that can effectively bridge this gap.”
Newman continued, “We look forward to partnering with AMSBIO to make this service accessible to researchers around the world working in different therapeutic areas.”